Citius Oncology, Inc. Financials
This page shows Citius Oncology, Inc. (CTOR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Citius Oncology’s dominant mechanic is a development-stage financing cycle: operating investment, inventory buildup, and continued dependence on new capital.
Cash conversion deteriorated sharply: operating cash flow moved from$126K in FY2024 to-$5.5M in FY2025 while net loss widened from-$21.1M to-$24.8M . The smaller cash outflow than accounting loss suggests that non-cash items or working-capital movements materially affected reported earnings, but the latest year still required cash financing.
Inventory rose from
External financing remains central: financing cash inflow reached
Financial Health Signals
Citius Oncology, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Citius Oncology, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Citius Oncology, Inc. reported a net loss of $24.8M while operations used $5.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Citius Oncology, Inc. reported an operating loss of $23.5M against $218K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Citius Oncology, Inc. reported -$24.8M in net income in fiscal year 2025. This represents a decrease of 17.1% from the prior year.
Citius Oncology, Inc. earned -$0.34 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 9.7% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Citius Oncology, Inc. held $3.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Citius Oncology, Inc.'s ROE was -55.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Citius Oncology, Inc. invested $6.4M in research and development in fiscal year 2025. This represents an increase of 30.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CTOR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M-10.4% | $1.7M-57.7% | $3.9M | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $492K+49.6% | $329K-58.3% | $789K | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $1.0M-25.1% | $1.3M-57.6% | $3.2M | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $218K-79.8% | $1.1M+6.0% | $1.0M | N/A | $938K-70.1% | $3.1M+148.3% | $1.3M | N/A |
| SG&A Expenses | $4.2M-82.1% | $23.6M+726.3% | $2.9M | N/A | $1.9M-16.1% | $2.2M-32.5% | $3.3M | N/A |
| Operating Income | -$8.7M+69.5% | -$28.6M-444.8% | -$5.3M | N/A | -$4.9M+33.8% | -$7.5M-16.8% | -$6.4M | N/A |
| Interest Expense | $198K+500.4% | $33K-27.9% | $46K | N/A | $161K | N/A | N/A | N/A |
| Income Tax | -$107K+53.6% | -$231K-187.5% | $264K | N/A | $264K0.0% | $264K0.0% | $264K | N/A |
| Net Income | -$8.9M+66.5% | -$26.6M-380.8% | -$5.5M | N/A | -$5.4M+30.6% | -$7.7M-16.2% | -$6.7M | N/A |
| EPS (Diluted) | -$0.08+70.4% | -$0.27-350.0% | -$0.060.0% | -$0.06+25.0% | -$0.08+27.3% | -$0.11-22.2% | -$0.09+10.0% | -$0.10 |
CTOR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $112.1M+11.3% | $100.7M-8.4% | $110.0M+8.9% | $100.9M+10.1% | $91.7M+0.3% | $91.4M+1.1% | $90.5M+7.2% | $84.4M |
| Current Assets | $42.7M+45.1% | $29.4M-20.8% | $37.1M+34.9% | $27.5M+50.4% | $18.3M+1.5% | $18.0M+5.6% | $17.1M+55.7% | $11.0M |
| Cash & Equivalents | $16.6M+529.2% | $2.6M-63.9% | $7.3M+85.9% | $3.9M+3504282.1% | $1120.0% | $1120.0% | $1120.0% | $112 |
| Inventory | $22.6M-0.1% | $22.7M+0.1% | $22.6M+1.6% | $22.3M+29.5% | $17.2M+12.2% | $15.3M+6.7% | $14.4M+73.9% | $8.3M |
| Accounts Receivable | $686K-36.4% | $1.1M-73.4% | $4.0M | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $71.7M+9.6% | $65.4M+26.9% | $51.6M-8.1% | $56.1M-5.5% | $59.3M+6.3% | $55.8M+13.4% | $49.2M+28.7% | $38.2M |
| Current Liabilities | $58.8M0.0% | $58.8M+31.5% | $44.7M-9.7% | $49.5M-6.6% | $53.0M+6.5% | $49.7M+14.6% | $43.4M+32.7% | $32.7M |
| Total Equity | $40.4M+14.5% | $35.3M-39.6% | $58.4M+30.2% | $44.9M+38.5% | $32.4M-9.1% | $35.6M-13.7% | $41.3M-10.5% | $46.1M |
| Retained Earnings | -$105.1M-9.3% | -$96.2M-38.2% | -$69.6M-8.6% | -$64.0M-8.5% | -$59.0M-10.0% | -$53.7M-16.8% | -$45.9M-17.0% | -$39.3M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
CTOR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M+29.3% | -$3.8M+47.9% | -$7.4M | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$2.0M-233.3% | -$600K+86.4% | -$4.4M | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $18.6M+8163.1% | -$231K-101.5% | $15.1M | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
CTOR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.1%-13.2pp | 80.3%+0.3pp | 80.0% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -583.5% | -1716.2% | -133.2% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -597.4% | -1596.0% | -140.3% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -22.1%+53.3pp | -75.4%-66.0pp | -9.5% | N/A | -16.6%+5.1pp | -21.7%-5.6pp | -16.1% | N/A |
| Return on Assets | -8.0%+18.5pp | -26.4%-21.4pp | -5.0% | N/A | -5.9%+2.6pp | -8.5%-1.1pp | -7.4% | N/A |
| Current Ratio | 0.73+0.2x | 0.50-0.3x | 0.83+0.3x | 0.56+0.2x | 0.350.0x | 0.360.0x | 0.39+0.1x | 0.34 |
| Debt-to-Equity | 1.78-0.1x | 1.86+1.0x | 0.88-0.4x | 1.25-0.6x | 1.83+0.3x | 1.57+0.4x | 1.19+0.4x | 0.83 |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.56), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Citius Oncology, Inc. Ranks
Frequently Asked Questions
Is Citius Oncology, Inc. profitable?
No, Citius Oncology, Inc. (CTOR) reported a net income of -$24.8M in fiscal year 2025.
What is Citius Oncology, Inc.'s return on equity (ROE)?
Citius Oncology, Inc. (CTOR) has a return on equity of -55.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Citius Oncology, Inc.'s operating cash flow?
Citius Oncology, Inc. (CTOR) recorded an outflow of $5.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Citius Oncology, Inc.'s total assets?
Citius Oncology, Inc. (CTOR) had $100.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Citius Oncology, Inc. spend on research and development?
Citius Oncology, Inc. (CTOR) invested $6.4M in research and development during fiscal year 2025.
What is Citius Oncology, Inc.'s current ratio?
Citius Oncology, Inc. (CTOR) had a current ratio of 0.56 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Citius Oncology, Inc.'s debt-to-equity ratio?
Citius Oncology, Inc. (CTOR) had a debt-to-equity ratio of 1.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Citius Oncology, Inc.'s return on assets (ROA)?
Citius Oncology, Inc. (CTOR) had a return on assets of -24.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Citius Oncology, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Citius Oncology, Inc. (CTOR) held $3.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.5M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Citius Oncology, Inc.'s Piotroski F-Score?
Citius Oncology, Inc. (CTOR) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Citius Oncology, Inc.'s earnings high quality?
Citius Oncology, Inc. (CTOR) reported a net loss of $24.8M while operations used $5.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Citius Oncology, Inc. cover its interest payments?
Citius Oncology, Inc. (CTOR) reported an operating loss of $23.5M against $218K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.